Quantitative analysis of myocardial fibrosis (Figure 4D) showed that aFGF-NP + UTMD could significantly reduce the degree of myocardial fibrosis in doxorubicin–induced heart failure compared with other treatment groups (p < 0.05). The gene discussed is FGF1; the disease is heart failure.